The Relationship Between Serum Homocysteine Levels and Vertebral Fractures by NAGAI Takashi et al.
Showa Univ J Med Sci 27（2）, 103～110, June 2015
The Relationship Between Serum Homocysteine Levels and  
Vertebral Fractures
Takashi NAGAI＊, Keizo SAKAMOTO, Sadaaki TSUTSUI,  
Takuma KURODA, Takaaki KANAZAWA and Katsunori INAGAKI
Abstract : Serum homocysteine and pentosidine levels have attracted attention as 
associated markers of bone quality, which affects bone strength.  We examined the 
relationship of serum homocysteine levels with existing vertebral fractures and renal 
function.  We evaluated 279 of 960 osteoporosis outpatients （12 men, 267 women ; 
mean age, 72 years） whose serum homocysteine levels had been measured in our 
department.  Using a glomerular ltration rate （GFR）-based chronic renal failure 
severity classication system, we divided patients into three groups : G1/G2, G3a/
G3b/G4, and G5.  We further divided the patients in the G1/G2 and G3a/G3b/
G4 groups into two subgroups on the basis of the presence of fractures.  Vertebral 
fractures were significantly more frequent when serum homocysteine levels were 
high in the G1/G2 group （P＝ 0.002）.  Serum homocysteine levels were lower in 
patients in the G1/G2 group than the G3a/G3b/G4 group despite the presence or 
absence of vertebral fractures （P＜ 0.001）.  Signicant differences in serum homo-
cysteine levels were also seen between patients with and without vertebral fractures 
in both the G1/G2 and G3a/G3b/G4 groups （P＝ 0.02）.  There were also signi-
cant correlations between GFR and serum homocysteine levels in both the G1/
G2 and G3a/G3b/G4 groups （correlation coefcients, -0.43 and -0.65, respectively ; 
P ＜ 0.001）.  A negative correlation was observed between serum homocysteine 
levels and GFR in the G1/G2 and G3a/G3b/G4 groups, and we were able to reaf-
rm that serum homocysteine levels are affected by renal function.  In the G1/G2 
group, the prevalence of vertebral fractures was signicantly higher in patients with 
high serum homocysteine levels.  Even if renal function was poor, serum homo-
cysteine levels were signicantly higher in patients with vertebral fractures.  Thus, 
serum homocysteine is a valid marker of bone quality.
Key words : osteoporosis, serum homocysteine, vertebral fractures, bone quality, glo-
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Introduction
　Bone strength is a combination of bone mineral density and bone quality, with the former 
contributing to 70％ of bone strength and the latter 30％1）.  Bone quality is conventionally 
assessed by bone turnover, microstructures, microfractures, and calcification.  However, serum 
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homocysteine and pentosidine levels are beginning to attract attention as associated markers of 
bone quality2）, because there is a correlation between serum pentosidine levels and vertebral 
fractures in women with type 2 diabetes mellitus3）; moreover, high serum homocysteine levels 
show a signicant association with osteoporotic fractures4, 5）.
　On the other hand, serum homocysteine and pentosidine levels are useful for the clinical 
assessment of atherosclerosis and renal dysfunction.  Homocysteine has two fates.  If there is 
a deciency of methionine, homocysteine may be remethylated to methionine.  If methionine 
stores are adequate, homocysteine may enter the transsulfuration pathway, where it is converted 
to cysteine.  Because methionine is an essential amino acid, cysteine synthesis can be sustained 
only if the dietary intake of methionine is adequate6）.  In cases of hyperhomocysteinemia, 
there is an increased risk of atherosclerosis, which leads to a greater incidence of heart attacks 
caused by coronary artery disease and cerebral haemorrhage7）.  Because vascular calcification 
affects renal function, and comorbid hyperhomocysteinemia is common in dialysis patients, it is 
thought that homocysteine levels are implicated in renal function.  Renal dysfunction, including 
hemodialysis, appears to be one cause of osteoporosis.  The causes of hyperhomocysteinemia in 
patients with renal dysfunction are thought to be : （1） decreased hepatic uptake of homocyste-
ine ; （2） decreased utilization of vitamin B6, vitamin B12, and folic acid, which are co-factors of 
the metabolizing enzymes ; and （3） the inhibition of metabolic factors leading to high levels of 
homocysteine being present in the blood8）.
　In the present study, a widely-used classication system dening the severity of renal dysfunc-
tion （G1-G5）, which is based on the glomerular filtration rate （GFR）9）, was used to group 
patients according to renal function.  Then, we investigated whether homocysteine levels in the 




　Out of a total of 960 osteoporosis outpatients whose serum homocysteine levels were mea-
sured in our department, we evaluated 279 patients （12 men and 267 women ; mean age, 72 
years） from a mixed treatment group, comprising 28 patients receiving vitamin D3, 15 receiving 
etidronate, 58 receiving alendronate, 59 receiving risedronate, 7 receiving minodronate, 20 receiv-
ing a selective estrogen receptor modulator （SERM）, 5 receiving parathyroid hormone （PTH）, 
and 87 not receiving any treatment.
　
Methods
　In a GFR-based classication system for the severity of chronic renal failure, G1 represents 
normal or high GFR levels, G2 represents normal or mildly decreased levels, G3a represents 
mildly to moderately decreased levels, G3b represents moderately to severely decreased levels, G4 
represents severely decreased levels, and G5 represents end-stage renal failure9）.  In the present 
study, patients were classied into two groups, G1/G2 and G3a/G3b/G4, while the patients in the 
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G5 group were excluded because of renal dysfunction （ve patients ; one man, four women ; 
mean age, 75.8 years）.  We further divided the G1/G2 group （203 patients ; 10 men, 193 
women ; mean age, 69.7 years） and the G3a/G3b/G4 group （71 patients ; one man, 70 women ; 
mean age, 79.4 years） into subgroups based on serum homocysteine levels and the prevalence 
of vertebral fractures.  We measured serum homocysteine levels and designated ≦ 11.7 nmol/
ml as ‘normal’ and＞ 11.7 nmol/ml as ‘high’.  In addition, we examined the correlation between 
serum homocysteine levels and GFR in the G1/G2 and G3a/G3b/G4 groups.  We also examined 
whether there was a difference in the frequency of fractures in the G1/G2 and G3a/G3b/G4 
groups within the normal and high serum homocysteine level groups.
Using serum creatinine （Cr） levels, GFR was calculated using the formulae :
　eGFR （ml/min/1.73 m2） ＝ 194 × Cr （µM）-1.094 × age （years）-0.287 for men ;
　eGFR （ml/min/1.73 m2） ＝ 194 × Cr-1.094 × age-0.287 × 0.739 for women9）.
　
Statistical analysis
　We analyzed differences in the frequency of existing vertebral fractures in the normal and 
high serum homocysteine level groups using the chi-squared test.  The correlation between serum 
homocysteine levels and GFR in the G1/G2 and G3a/G3b/G4 groups was examined using the 
Spearman rank correlation coefcient.  The Mann-Whitney U test was used to analyze the rela-
tionship between vertebral fractures and serum homocysteine levels in the G1/G2 and G3a/G3b/
G4 groups.  Serum homocysteine levels are presented as mean levels ± standard deviations, and 
the two-tailed signicance level was set at 5％.  Stat Flex ver. 6 statistical software （Artech Co., 
Ltd., Osaka, Japan） was used for all statistical analyses.
　
Ethical considerations
　The Ethical Committee of Showa University School of Medicine （Tokyo, Japan） approved the 
protocols used in this study and the personal information of the study participants was protected 
（permit no. 1287）.
Results
Frequency of existing vertebral fractures, based on serum homocysteine levels and GFR classica-
tion
　In the normal serum homocysteine level subgroup of the G1/G2 group, there were 57 patients 
（33.3％） with vertebral fractures and 114 patients （66.7％） without vertebral fractures.  In the 
high serum homocysteine level subgroup of the G1/G2 group, there were 20 patients （62.5％） 
with vertebral fractures and 12 patients （37.5％） without （P ＝ 0.002 ; Fig. 1a）.  In the G1/G2 
group, the number of vertebral fractures increased as the level of homocysteine increased.
　In the normal serum homocysteine subgroup of the G3a/G3b/G4 group, there were 17 patients 
（44.7％） with vertebral fractures and 21 patients （55.3％） without.  In the high serum homocys-
teine level subgroup of the G3a/G3b/G4 group, there were 21 patients （63.6％） with vertebral 
fractures and 12 patients （36.4％） without, but there were no significant differences between 
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groups （P ＝ 0.11 ; Fig. 1b）.  As homocysteine was inuenced by renal function in the G3a/G3b/
G4 group, it was unclear if homocysteine levels had an effect on fractures.
　
Relationship between serum homocysteine levels and GFR classication, based on existing vertebral 
fractures
　Among the patients without existing vertebral fractures, the mean serum homocysteine level 
was 8.6 ± 3.7 nmol/ml in the 126 patients in the G1/G2 group and 11.6 ± 4.0 nmol/ml in the 33 
patients in the G3a/G3b/G4 group （P ＜ 0.001 ; Fig. 2a）.
　Among the patients with existing vertebral fractures, the mean serum homocysteine level was 
Fig. 1.  Percentage （％） of patients with or without vertebral fractures in the normal and high serum 
homocysteine subgroups of the glomerular filtration rate （GFR）-based classification groups, 
（a） G1/G2, and （b） G3a/G3b/G4. ＊P＝ 0.002, significant difference between subgroups.
Fig. 2.  Mean serum homocysteine levels （nmol/ml） in patients in the glomerular filtration rate 
（GFR）-based classification groups, G1/G2 and G3a/G3b/G4, （a） without, and （b） with 
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10.3 ± 3.4 nmol/ml in the 77 patients in the G1/G2 group and 13.9 ± 5.5 nmol/ml in the 38 
patients in the G3a/G3b/G4 group （P ＜ 0.001 ; Fig. 2b）.
　
Relationship between serum homocysteine levels and vertebral fractures, based on GFR classica-
tion
　Among the patients in the G1/G2 group, the mean serum homocysteine level was 10.3 ± 
3.4 nmol/ml, in the 77 patients with vertebral fractures, whereas it was 8.6 ± 3.7 nmol/ml in the 
Fig. 3.  Mean serum homocysteine levels （nmol/ml） in patients with and without vertebral fractures in 
the glomerular filtration rate （GFR）-based classification groups, （a） G1/G2, and （b） G3a/G3b/
G4. ＊P ＜ 0.02 ; ＊＊P ＜ 0.001, significant difference between groups.
Fig. 4.  Correlation between serum homocysteine levels （nmol/ml） and glomerular filtration rate （GFR ; ml/
min/1.73 m2） in patients in the GFR-based classification group, （a） G1/G2 （Spearman rank correlation 
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126 patients without vertebral fractures （P ＜ 0.001 ; Fig. 3a）.
　Among the patients in the G3a/G3b/G4 group, the mean serum homocysteine level was 13.9 ± 
5.5 nmol/ml in the 38 patients with vertebral fractures, whereas it was 11.6 ± 4.0 nmol/ml in the 
33 patients without vertebral fractures （P ＜ 0.02 ; Fig. 3b）.
　
Correlation between serum homocysteine levels and GFR classication groups
　In both the G1/G2 and G3a/G3b/G4 groups, there was a signicant correlation between GFR 
and serum homocysteine levels （Spearman rank correlation coefcients, -0.43 and -0.65, respec-
tively ; P ＜ 0.001 ; Figs. 4a and 4b）.
Discussion
　The serum homocysteine level is considered a useful marker of bone quality and renal func-
tion.  Our results showed that in the G1/G2 group, serum homocysteine levels showed signicant 
differences between patients with and without vertebral fractures.  From these results, it is pos-
sible to assume that serum homocysteine can be used as an index of existing vertebral fractures 
when renal function is normal or mildly decreased.  In the G3a/G3b/G4 group, there was no 
difference in the number of patients with or without an existing vertebral fracture ; however, 
serum homocysteine levels increased with vertebral fractures irrespective of the GFR-based renal 
dysfunction classication grade.  Yokokawa et al 10） reported normal serum homocysteine levels in 
patients with tibial diaphyseal fractures who were taking bisphosphonates.  Thus, we believe that 
serum homocysteine levels do not increase because of fractures ; instead, we hypothesize that 
fractures may occur more frequently in patients with relatively higher homocysteine levels.
　Our results indicated a correlation between serum homocysteine and GFR in both the G1/
G2 and G3a/G3b/G4 groups, which conrmed that homocysteine is affected by renal function. 
Homocysteine is an amino acid produced in the metabolic pathway of the essential amino acid, 
methionine, and is resynthesized into methionine through the action of folic acid and vitamin 
B12 6, 11）.  As a result, oxidative stress is increased due to high levels of homocysteine.  In addi-
tion, vitamin B6 , B12 , and folic acid insufciencies cause abnormalities in bone collagen cross-
linking12） and bone becomes fragile despite the same bone mineral density.  Low bone mineral 
density is an independent risk factor for fractures4, 5, 12-15）.  In addition, serum homocysteine levels 
are not correlated with the levels of bone metabolism markers such as bone alkaline phospha-
tase, deoxypyridinoline, and bone tartrate-resistant acid phosphatase-5b.  Thus, bone metabolism 
markers are also considered independent factors for predicting fracture risk4）.  In contrast, methi-
onine is mainly metabolized by the kidneys ; therefore, when renal function decreases, normal 
metabolism is disturbed, causing homocysteine levels to increase.  When hyperhomocysteinemia 
continues, it creates a negative cycle of further renal dysfunction associated with renal artery 
atherosclerosis 7，8）.
　Hormones involved in bone resorption include vitamin D which is hydroxylated in the liver 
and proximal renal tubules and converted to the active form of vitamin D3.  The rst hydroxyl-
ation occurs at the 25-position, and is catalyzed by a specic hydroxylase in the liver.  The prod-
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uct of the reaction, 25-hydroxycholecalciferol （25-OH-D3）, is the predominant form of vitamin 
D in the plasma and the major storage form of the vitamin.  25-OH-D3 is further hydroxylated 
at the 1 position by 25-OH-D3 1-hydroxylase found primarily in the kidney, resulting in the 
formation of 1,25-dihydroxycholecalciferol 16）.  The active form of vitamin D3 promotes the active 
absorption of calcium and phosphorus in the intestinal tract.  Therefore, decreased renal function 
leads to impaired hydroxylation of vitamin D, causing osteoporosis and making vertebral fractures 
more likely to occur.
　In cases with high bone turnover and increased bone resorption, the use of bisphosphonates 
and SERM is recommended for the inhibition of bone turnover.  In contrast, there are cases 
in which vertebral fractures occur easily even when bone mineral density is high, such as in 
diabetes ; therefore, high bone mineral density is not necessarily a good indicator of bone quality. 
When bone mineral density is low and associated markers of bone quality are high, increas-
ing bone mineral density should be given priority and administration of bisphosphonates and 
PTH is recommended.  However, bisphosphonates cannot easily improve the levels of markers 
associated with bone quality1）.  Therefore, clinically, SERM, PTH, and eldecalcitol are used to 
improve bone quality.  PTH is considered effective in either case, but it can only be used for a 
maximum of 2 weeks because side effects need to be considered.  SERM also increases bone 
mineral density, but the rate of increase is small compared with bisphosphonates 17）.  Selection 
of a drug or drug combination varies according to the number of existing vertebral fractures, 
bone mineral density, bone metabolism markers, the state of bone quality, complications such as 
diabetes or chronic respiratory disease, the presence or absence of steroids or dental treatment, 
duration after menopause, and the state of renal function ; therefore, a personalized medication 
regimen is necessary for each individual case.
　There were some limitations in this study.  First, there was a number of patients who received 
different osteoporosis medications, while some did not receive any drugs.  Second, the SERM 
and PTH preparations were used to improve bone quality ; therefore, these drugs may have 
affected serum homocysteine levels.  We plan to continue our examination of whether serum 
homocysteine levels can be improved through osteoporosis treatment.
　In conclusion, among patients in the G1/G2 group of the chronic renal failure GRF-based 
classication （normal to mild renal dysfunction）, there was a signicantly higher prevalence of 
vertebral fractures when serum homocysteine levels were high.  Even in patients with poor renal 
function, serum homocysteine levels were signicantly higher when there were vertebral fractures. 
Thus, our results suggest that the serum homocysteine level can be considered a valid marker of 
bone quality.
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